Waverley Pharma Inc (WAVE) Fair Value & Analysis
Healthcare · CA · Market cap C$810K
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 7 days ago
Share price +150.0% over the past month.
Price vs Fair Value (12 months)
12‑month range C$0.0100 – C$0.0350 · fair‑value band C$0.0700 – C$0.1100 · the C$0.0250 price screens below the C$0.0900 fair value. As of Jun 23, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Waverley Pharma Inc (WAVE) currently trades at C$0.0250, while our model-based Fair Value estimate is C$0.0900 — implying the stock looks roughly 260.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Waverley Pharma Inc generated revenue of C$1.2M at a net margin of -50.5%. Revenue declined 26.6% year over year. Net debt stands at C$3.2M. Fundamentals as of Jun 23, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 23, 2026. TTM = trailing twelve months.
About the company
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Waverley Pharma Inc reported revenue of C$1.3M in FY2025 versus C$1.8M in FY2021, a compound −6.3%/yr. Reported net income was −C$499K in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Waverley Pharma Inc (WAVE) undervalued?
What is the fair value of WAVE?
What is the quality score of WAVE?
What is the revenue of Waverley Pharma Inc (WAVE)?
What is the net profit margin of WAVE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.